Introduction
Rheumatism is a category of chronic diseases that seriously affect the quality of life of patients, including various types such as rheumatism arthritis, high-line spinalitis and silver crumb arthritis. With the development of medicine, biological agents play an important role in the treatment of rheumatism immunopathy, one of the representative drugs.
II. ACTIVE MECHANISMS OF THE ADAM UNIT
It is a monoclonic antigens of all-people anti-tumour necrosis-alpha (TNF-alpha). TNF-α is at the centre of the rheumatism immune system, which induces inflammation, activates immunosuppressive cells, promotes glitch growth and cartilage damage, etc. By combining TNF-α with a specific type of TNF-α, it is preventing its interaction with a cell surface receptor, thereby inhibiting the biological activity of TNF-α, reducing inflammatory response, reducing joint pain, swelling and slowing the course of joint damage.
Adaptation certificates
(i) Rheumatism
In the case of patients with moderate severe rheumatism, especially those with poor or unsatisfied response to the traditional improvement of their condition (DMARDs) treatment, ATM single resistance can significantly improve their joint symptoms and signs. It can reduce disease activity, improve the quality of life of patients and reduce disability rates. The efficacy of treatment is even more significant when it comes to DMARDs, such as the joint acacias.
(ii) Strong straight spinal cord
In the treatment of direct spinal disease, Adawood is effective in reducing back pain, rigidity and improving spinal activity. It can contain the inflammation of the spinal column and the luminum joint, and has a role in slowing the evolution of the cylindrical evolution of the spinal column. The benefits are more pronounced for patients who are diagnosed early and applied in a timely manner.
(iii) Silver crumb arthritis
Artificial pain, swelling and restriction of activities for people with silver crumb arthritis can be mitigated, while also improving skin crumbs. New rashes can be reduced, skin red spots can be improved, skin crumbs can be improved, and the overall appearance and life confidence of patients can be improved.
(iv) Other rheumatism
Among the diseases associated with immunopathy, such as early childhood arthritis and cronosis, the single-use resistance of Adam has also shown some efficacy in providing new options for the treatment of these incurable diseases.
IV. USE METHODOLOGY
(i) Dose
The general recommended dose is 40 mg per week under the skin, but in certain special cases, for example, the weight factor or the severity of the condition may require an adjustment. Medical advice should be strictly followed in their use.
(ii) Injection
It is common to choose the parts of the abdominal, exterior thighs, which are rich in fat and self-injecting. Patients or their families can inject themselves at home after receiving professional training.
(iii) Treatment process
The treatment process depends on the patient ‘ s condition and treatment response. Usually, after the symptoms have abated, there is still a need for a period of time to consolidate the efficacy. Some patients may need long-term maintenance treatment, which requires periodic assessment of changes in conditions to adjust the treatment programme.
V. SECURITY ISSUES
(i) Risk of infection
TNF-α, which is inhibited by the Adam unilaterally, may affect the immune defences of the organism and increase the risk of infection. Common infections include upper respiratory infections, pneumonia and tuberculosis. Patients need to be screened fully for infection before use, including for tuberculosis fungus. In the course of treatment, patients who experience infections such as fever and cough should be treated in a timely manner.
(ii) Injection sector response
Some patients may have local reactions, such as swelling, pain, itching, etc., in the injection area, generally with light symptoms and self-resorting. If the response is severe, the injection area needs to be adjusted or treated accordingly.
(iii) Other adverse effects
There may also be adverse effects such as abnormal blood system and liver function, but relatively few. Indicators such as blood protocol, liver function etc. need to be monitored regularly during treatment.
Monitoring and follow-up
Regular follow-up visits are required for the treatment of rheumatism in the use of the Adawood monolithic. These include the assessment of the patient ‘ s joint symptoms, signs, disease activity scores (e.g. DAS28, etc.), examination laboratory indicators such as blood sunk, C reaction protein, blood routine, liver function, etc. At the same time, attention needs to be paid to changes in the quality of life of patients and to the adverse effects of drugs, and to the timely adjustment of treatment programmes based on this information to ensure the effectiveness and safety of treatment.
Conclusion
The importance of Adam alone in the treatment of rheumatism and immunization has created hope for improvement for many patients. However, it needs to be used in a manner that takes full account of its accommodatives, methods of use, safety, etc., and maximizes its therapeutic effects, reduces the occurrence of adverse reactions and improves the quality of life of persons with rheumatizing immunodeficiency syndrome through standardized treatment and close monitoring. At the same time, as the research is well advanced, our understanding of the Adam unilaterally will continue to improve and optimize its clinical application.
